IKT
Inhibikase Therapeutics, Inc.
$1.67
0.00%
$220.5M
No data for this timeframe.
Vol
Market Cap$220.5M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders41 funds
Inst. Value$40.0M
Inst. Activity14 buys / 1 sells
Reddit Sentiment67° Warm
SEC Reports3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001750149·Prev Close $1.67
Recent Activity
May 12, 2026
SEC
Inhibikase Therapeutics reported Q1 2026 results with a net loss of $16.4M ($0.10/share), slightly wider than the $13.7M
8-K — Impact 4/10
May 12, 2026
SEC
Inhibikase reported a Q1 2026 net loss of $0.10 per share, slightly missing the $0.09 consensus, but operating expenses
PRESS-RELEASE — Impact 6/10
Apr 7, 2026
SEC
Inhibikase Therapeutics announced the enrollment of the first patient in its global Phase 3 IMPROVE-PAH trial for IKT-00
8-K — Impact 5/10
Feb 21, 2026
Insider
Aurentz Vincent disposed of 255,299 shares
Director
Feb 21, 2026
Insider
Cabell Christopher disposed of 338,282 shares
President & Head of R&D
Feb 21, 2026
Insider
Munshi Amit disposed of 19,089 shares
Director
Inst.
BlackRock, Inc. — ADD
6,303,433 shares ($10.6M)
Inst.
STATE STREET CORP — DOUBLED
1,685,816 shares ($2.8M)
Price Targets
$5.88
+251.8% upside
Strong Buy
Current $1.67
Low $3.00
Median $5.50
High $8.00
8 analysts
$3.00
$8.00
Analyst Ratings
3Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 10, 2026 | Oppenheimer | INITIATE | Outperform |
| Mar 4, 2026 | Ladenburg Thalmann | INITIATE | Buy |
| Jan 21, 2026 | B of A Securities | INITIATE | Buy |
| Dec 17, 2025 | Freedom Broker | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.09 | $-0.09 — $-0.09 | 2 | |
| Next Q | $-0.09 ▲ +10.0% | $-0.09 — $-0.09 | 2 | |
| Current FY | $-0.37 | $-0.38 — $-0.36 | 2 | |
| Next FY | $-0.38 | $-0.39 — $-0.37 | -3% YoY | 2 |
Latest Reports
NEUTRAL
8-K
4/10
Inhibikase Therapeutics reported Q1 2026 results with a net loss of $16.4M ($0.10/share), slightly wider than the $13.7M
May 12, 2026
MIXED
PRESS-RELEASE
6/10
Inhibikase reported a Q1 2026 net loss of $0.10 per share, slightly missing the $0.09 consensus, but operating expenses
May 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $10.6M | ADD |
| Blackstone Inc. | $10.0M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.5M | — |
| STATE STREET CORP | $2.8M | DOUBLED |
| CITADEL ADVISORS LLC | $1.9M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 21, 2026 | Aurentz Vincent | D | $0.00 |
| Feb 21, 2026 | Cabell Christopher | D | $0.00 |
| Feb 21, 2026 | Munshi Amit | D | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
41 institutional holders with $40.0M total value (23,866,419 shares) as of 2026-Q1. Top holders: BlackRock,, Blackstone, VANGUARD. Net buying activity: 14 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6,303,433 | $10.6M | 26.5% | ADD +90.7% |
| 2 | Blackstone Inc. | 5,938,276 | $10.0M | 24.9% | DOUBLED +125.1% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 4,450,665 | $7.5M | 18.7% | — |
| 4 | STATE STREET CORP | 1,685,816 | $2.8M | 7.1% | DOUBLED +203.8% |
| 5 | CITADEL ADVISORS LLC | 1,102,585 | $1.9M | 4.6% | — |
| 6 | TWO SIGMA INVESTMENTS, LP | 847,611 | $1.4M | 3.6% | — |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 617,730 | $1.0M | 2.6% | — |
| 8 | VANGUARD FIDUCIARY TRUST CO | 566,999 | $952.6K | 2.4% | — |
| 9 | Nuveen, LLC | 472,399 | $793.6K | 2.0% | DOUBLED +500.6% |
| 10 | BANK OF AMERICA CORP /DE/ | 322,704 | $542.1K | 1.4% | DOUBLED +595.3% |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 235,414 | $395.5K | 1.0% | ADD +54.6% |
| 12 | MORGAN STANLEY | 164,259 | $276.0K | 0.7% | DOUBLED +106.1% |
| 13 | BLAIR WILLIAM & CO/IL | 157,988 | $265.4K | 0.7% | — |
| 14 | GOLDMAN SACHS GROUP INC | 149,857 | $251.8K | 0.6% | — |
| 15 | DEUTSCHE BANK AG\ | 122,442 | $205.7K | 0.5% | DOUBLED +123.0% |
| 16 | FMR LLC | 71,963 | $120.9K | 0.3% | ADD +25.4% |
| 17 | MetLife Investment Management, LLC | 62,913 | $105.7K | 0.3% | — |
| 18 | RHUMBLINE ADVISERS | 58,717 | $98.6K | 0.2% | — |
| 19 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 50,284 | $84.5K | 0.2% | ADD +74.1% |
| 20 | SEI INVESTMENTS CO | 47,962 | $80.6K | 0.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 3,305,574 | 6,303,433 | +90.7% | $10.6M | 2026-Q1 |
| STATE STREET CORP | DOUBLED | 554,849 | 1,685,816 | +203.8% | $2.8M | 2026-Q1 |
| Nuveen, LLC | DOUBLED | 78,659 | 472,399 | +500.6% | $793.6K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 46,411 | 322,704 | +595.3% | $542.1K | 2026-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 152,298 | 235,414 | +54.6% | $395.5K | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 79,682 | 164,259 | +106.1% | $276.0K | 2026-Q1 |
| DEUTSCHE BANK AG\ | DOUBLED | 54,909 | 122,442 | +123.0% | $205.7K | 2026-Q1 |
| FMR LLC | ADD | 57,374 | 71,963 | +25.4% | $120.9K | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 28,875 | 50,284 | +74.1% | $84.5K | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | 13,146 | 16,934 | +28.8% | $28.4K | 2026-Q1 |
| CWM, LLC | DOUBLED | 73 | 16,419 | +22391.8% | $27.6K | 2026-Q1 |
| Legal & General Group Plc | ADD | 5,504 | 9,404 | +70.9% | $15.8K | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 10,814 | 6,517 | -39.7% | $10.9K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 1 | 383 | +38200.0% | $644.00 | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 30,606 | 50,874 | +66.2% | $86.00 | 2026-Q1 |
| CWM, LLC | DOUBLED | 19 | 73 | +284.2% | — | 2025-Q4 |
| Blackstone Inc. | DOUBLED | 2,638,276 | 5,938,276 | +125.1% | $12.2M | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 3,273,339 | 4,558,604 | +39.3% | $9.3M | 2025-Q4 |
| MORGAN STANLEY | ADD | 56,019 | 79,682 | +42.2% | $163.3K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 45,745 | 67,833 | +48.3% | $139.1K | 2025-Q4 |
| FMR LLC | TRIM | 105,770 | 57,374 | -45.8% | $117.6K | 2025-Q4 |
| DEUTSCHE BANK AG\ | TRIM | 80,496 | 54,909 | -31.8% | $112.6K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 17,102 | 46,411 | +171.4% | $95.1K | 2025-Q4 |
| Russell Investments Group, Ltd. | ADD | 7,702 | 10,814 | +40.4% | $22.2K | 2025-Q4 |
| STATE STREET CORP | ADD | 397,812 | 507,749 | +27.6% | $822.6K | 2025-Q3 |
3 unique insiders with 3 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 21, 2026 | Aurentz Vincent | Director | D | 255,299 | — | — |
| Feb 21, 2026 | Cabell Christopher | President & Head of R&D | D | 338,282 | — | — |
| Feb 21, 2026 | Munshi Amit | Director | D | 19,089 | — | — |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 5.0/10.
NEUTRAL
8-K
4/10
Inhibikase Therapeutics reported Q1 2026 results with a net loss of $16.4M ($0.10/share), slightly w
May 12, 2026
MIXED
PRESS-RELEASE
6/10
Inhibikase reported a Q1 2026 net loss of $0.10 per share, slightly missing the $0.09 consensus, but
May 12, 2026
NEUTRAL
8-K
5/10
Inhibikase Therapeutics announced the enrollment of the first patient in its global Phase 3 IMPROVE-
Apr 7, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 3 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.88 mean target
+251.8% upside
Strong Buy (1.13)
$3.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $1.67 |
| Target Low | $3.00 |
| Target Mean | $5.88 |
| Target Median | $5.50 |
| Target High | $8.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.13) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.09 | $-0.09 | $-0.09 | — | +0.0% | — | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.09 | $-0.09 | $-0.09 | — | +10.0% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-0.37 | $-0.38 | $-0.36 | — | +0.0% | 0↑ 1↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-0.38 | $-0.39 | $-0.37 | -2.7% | +0.0% | 0↑ 1↓ | $0.0B | 33.3% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.090 | |
| 7d ago | $-0.090 | |
| 30d ago | $-0.090 | |
| 60d ago | $-0.090 | |
| 90d ago | $0.000 | -0.090 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 10, 2026 | Oppenheimer | INITIATE | — | Outperform |
| Mar 4, 2026 | Ladenburg Thalmann | INITIATE | — | Buy |
| Jan 21, 2026 | B of A Securities | INITIATE | — | Buy |
| Dec 17, 2025 | Freedom Broker | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 22, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
Recent Reddit Threads
May 12, 2026
earnings
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
<p align="justify">WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a cli
May 12, 2026
earnings_calendar
IKT Q1 2026 Earnings Scheduled — 2026-05-12
Apr 21, 2026
short_volume
Short Volume: IKT — 59.8% short (0.9M / 1.5M)
Short: 927,385 | Exempt: 1,000 | TRF Vol: 1,549,771 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
Apr 3, 2026
other
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), tod
Mar 26, 2026
earnings
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
<p align="justify">WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a c
Mar 25, 2026
earnings_calendar
IKT Q4 2025 Earnings After Market Close — 2026-03-25
Feb 5, 2026
short_interest
FTD: IKT — 320,771 shares ($0.5M) failed to deliver
Settlement: 20260205, Price: $1.56, FTD Value: $500,402.76, INHIBIKASE THERAPEUTICS INC CO